newsfilter
← Latest News
GlobeNewswire·

DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights

Reported positive Phase 1 proof-of-concept data supporting the further development of lead oral IL-17 antagonist, DC-806, as potential best-in-class oral agent for psoriasisDemonstrated direct inhibition of a cytokine